Showing 3371-3380 of 5689 results for "".
- Allegro Ophthalmics to Present the Results of Its Phase 2 Risuteganib Intermediate Dry AMD Study at EURETINAhttps://modernod.com/news/allegro-ophthalmics-to-present-the-results-of-its-phase-2-risuteganib-intermediate-dry-amd-study-at-euretina/2476845/Allegro Ophthalmics announced that the results of its US phase 2 study evaluating risuteganib (Luminate) for the treatment of intermediate nonexudative age-related macular degeneration (dry AMD) will be presented during the European Society of Retina Specialists (EURETINA) Congress that is being
- AmblyoPlay Now Offers its Vision Therapy Solution for Lazy Eye in the United Stateshttps://modernod.com/news/amblyoplay-now-offers-its-vision-therapy-solution-for-lazy-eye-in-the-united-states/2476828/AmblyoPlay, a home-based vision therapy solution for children and adults with amblyopia (lazy eye), mild strabismus (crossed or turned eye) or convergence insufficiency (eyes unable to focus together), announced the launch of its software-based vision therapy solution in the U.S. market. I
- AcuFocus Completes Study Enrollment for U.S. IDE Clinical Trial of IC-8 Lenshttps://modernod.com/news/acufocus-completes-study-enrollment-for-u-s-ide-clinical-trial-of-ic-8-lens/2476806/AcuFocus announced that it has completed enrollment in its pivotal US investigational device exemption (IDE) study of the company’s IC-8 small aperture IOL. FDA granted approval of the company’s IDE on November 21, 2018, and the Investigational Review Board approved the study just 5
- Glaukos Announces Agreement to Buy Avedro in All-Stock Dealhttps://modernod.com/news/glaukos-announces-agreement-to-buy-avedro-in-all-stock-deal/2479551/In a move to diversify its offerings and expand its corneal health franchise, Glaukos agreed to acquire cross-linking company Avedro in an all-stock transaction.
- Harrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Anti-Microbial Ophthalmic and Otic Therapeuticshttps://modernod.com/news/harrow-health-forms-stowe-pharmaceuticals-subsidiary-to-develop-anti-microbial-ophthalmic-and-otic-therapeutics/2479553/Harrow Health announced that its newly formed subsidiary, Stowe Pharmaceuticals, has entered into an agreement with TGV Health to acquire worldwide rights to the Zian anti-microbial molecule for ophthalmic and otic uses. Zian is a patented small molecule that is water soluble, colorless,
- Iveric bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapyhttps://modernod.com/news/iveric-bio-announces-successful-advancement-of-lca10-minigene-program-and-expansion-of-orphan-gene-therapy/2476762/Iveric bio announced that the company has exercised its option and entered into an exclusive global license agreement with the University of Massachusetts Medical School for rights to develop and commercialize mutation independent novel adeno-associated virus (AAV) gene therapy product candidates
- Genentech/Roche Complete Enrollment in Archway Phase 3 Study of the Port Delivery System with Ranibizumab in Wet AMDhttps://modernod.com/news/genentech-roche-complete-enrollment-in-archway-phase-3-study-of-the-port-delivery-system-with-ranibizumab-in-wet-amd/2476737/Genentech and Roche have completed patient enrollment in the phase 3 Archway (
- Trefoil Therapeutics Raises $28 Million Series A to Advance Engineered FGF-1 for the Treatment of Corneal Diseaseshttps://modernod.com/news/trefoil-therapeutics-raises-28-million-series-a-to-advance-engineered-fgf-1-for-the-treatment-of-corneal-diseases/2476735/Trefoil Therapeutics announced it raised $28 million in an oversubscribed Series A financing. The company is developing novel engineered fibroblast growth factor-1 proteins (eFGF-1) as a regenerative pharmacologic therapy to treat serious corneal endothelial diseases and epithelial disorders.
- Zeiss Marks Milestone for its New North America High Tech Site in Dublin, Californiahttps://modernod.com/news/zeiss-marks-milestone-for-its-new-north-america-high-tech-site-in-dublin-california/2476730/Zeiss announced that it has completed the “steel topping out” phase of its new high tech site in the San Francisco Bay Area. The new center will encompass 208,650 square feet with three floors. It is scheduled for completion in the fourth quarter of 2020 and will bring together multiple Ze
- Market Scope: Booming Demand, Surgical Planning Integration Drive Growth in Ophthalmic Diagnostic Markethttps://modernod.com/news/market-scope-booming-demand-surgical-planning-integration-drive-growth-in-ophthalmic-diagnostic-market/2476723/Market Scope estimates that the ophthalmic diagnostic equipment market will total $3.2 billion in 2019, and the firm expects it to increase to $3.8 billion in 2024—for a compound annual growth rate of 3.9 percent. Contributing factors include a rising global population, with an expanding elderly